What Is the NAD+ Salvage Pathway? How Your Cells Recycle NAD+ Every Day

Every cell in the body faces the same quiet logistical challenge, hundreds of times a second: nicotinamide adenine dinucleotide, commonly known as NAD+, is constantly being broken down as it fuels essential processes, yet cells cannot simply run out. They need a continuous resupply system working in the background at all times.

That system is called the NAD+ salvage pathway, and it is responsible for regenerating the vast majority of the NAD+ used in adult human tissue on a daily basis (Sun et al., 2025). Unlike the two other NAD+ biosynthesis routes, the de novo pathway, which builds NAD+ from dietary tryptophan, and the Preiss-Handler pathway, which uses nicotinic acid, the salvage pathway is unique in that it recycles a by-product the cell has already generated, rather than starting from raw dietary material each time (Chini et al., 2024). Understanding exactly how this recycling system works is essential to understanding NAD+ metabolism itself, independent of any specific supplement or precursor.

Why Is It Called a "Salvage" Pathway?

The name reflects precisely what the pathway does. When NAD+-consuming enzymes such as sirtuins, PARPs and CD38 use NAD+ to carry out their functions, they don't destroy the molecule's core components entirely. Instead, they break it down and release nicotinamide (NAM) as a by-product (Chini et al., 2024).

Rather than treating this by-product as waste, cells "salvage" it, funnelling it back through a dedicated series of enzymatic steps that reconstruct it into fresh, usable NAD+. This is fundamentally more efficient than continuously synthesising NAD+ from scratch, and it's the reason the salvage pathway handles most of the body's day-to-day NAD+ turnover (Chini et al., 2024).

The Salvage Pathway, Step by Step

The pathway itself follows a defined, three-enzyme sequence, each step converting one molecule into the next until NAD+ is fully reconstructed.

Step one: NAM to NMN. Nicotinamide phosphoribosyltransferase, or NAMPT, catalyses the conversion of nicotinamide into nicotinamide mononucleotide (NMN), combining it with 5′-phosphoribosyl pyrophosphate in the process (Nature Metabolism patent literature, cited in ScienceDirect Topics, n.d.). This is widely described as the rate-limiting step of the entire pathway, meaning the amount of active NAMPT available effectively sets the pace at which the whole system can regenerate NAD+.

Step two: NMN to NAD+. NMN, together with ATP, is converted into NAD+ by a family of enzymes called nicotinamide mononucleotide adenylyltransferases, or NMNAT. There are three NMNAT isoforms in mammals, NMNAT1, NMNAT2 and NMNAT3, each localised to a different part of the cell, the nucleus, cytosol and mitochondria, respectively, meaning NAD+ regeneration effectively occurs locally within each compartment rather than through a single, centralised process (ScienceDirect Topics, n.d.).

An alternative entry point: nicotinamide riboside. A related precursor, nicotinamide riboside (NR), can also feed into this pathway. Rather than being generated from NAD+ consumption directly, NR is phosphorylated inside the cell by nicotinamide riboside kinases 1 and 2 (NRK1 and NRK2) to form NMN, joining the same pathway at step two (PubMed, 2021).

Taken together, this means the salvage pathway has two practical entry points for supplementation: nicotinamide itself, which re-enters at step one, and nicotinamide riboside, which enters closer to step two, bypassing the NAMPT-catalysed conversion entirely.

How Do NAD+ Precursors Actually Get Into Cells?

This is a more complicated question than it first appears, and one that matters directly for anyone taking an NAD+ precursor supplement.

Nicotinamide riboside is taken up into cells via non-specific channels called equilibrative nucleoside transporters (ENTs) (nmn.com, 2021). Nicotinamide mononucleotide, by contrast, has a more debated route of entry. One study identified the gene Slc12a8 as encoding a specific NMN transporter, highly expressed in the mouse small intestine, and found that Slc12a8 deficiency significantly decreased NAD+ levels in the intestinal lining (Grozio et al., 2019).

However, more recent research examining orally administered NMN and NR in mice using detailed NAD+ metabolomics found that only a small portion of either compound was directly absorbed intact from the small intestine. The majority instead underwent gut microbiota-mediated conversion into nicotinic acid (NA) before being absorbed, meaning the compounds effectively entered the body via the separate Preiss-Handler pathway rather than the salvage pathway as originally assumed (Mori et al., 2025).

This finding is a genuinely important piece of nuance: it suggests that oral NAD+ precursor supplementation may work partly through indirect routes involving gut microbiota metabolism, rather than through the direct cellular uptake mechanism the salvage pathway diagram might suggest at first glance.

Why Does the Salvage Pathway Matter So Much for Ageing?

The salvage pathway's central importance to ageing biology stems from a straightforward mathematical reality: cellular NAD+ levels typically sit within a narrow steady-state range of roughly 200 to 500 micromolar, and because NAD+ is consumed constantly by sirtuins, PARPs and CD38, this level can only be maintained if regeneration keeps pace with consumption (ScienceDirect Topics, n.d.).

Research shows that NAMPT levels decrease with age, directly slowing the rate-limiting step of the salvage pathway, while CD38 activity simultaneously increases, accelerating NAD+ breakdown (Chini et al., 2024). This combination, a slower recycling system paired with faster consumption, is now understood as a central mechanism behind age-related NAD+ decline, distinct from any single enzyme acting in isolation.

The Salvage Pathway in Specific Tissues

Because the salvage pathway operates locally within each tissue, its efficiency can vary considerably depending on metabolic demand.

Skeletal muscle, a tissue with particularly high and continuous energy requirements, relies heavily on NAMPT-driven salvage pathway activity to sustain NAD+ levels, and research shows this pathway becomes measurably less efficient in ageing muscle, as well as in conditions such as type 2 diabetes and skeletal muscle injury (Su et al., 2024). Encouragingly, the same body of research found that exercise can help support salvage pathway function specifically within muscle tissue, offering a direct, non-pharmacological route to preserving this system with age.

Separately, research on cardiac tissue has found that NAD+ precursor supplementation, working through this same salvage pathway, can help attenuate cardiac ageing via activation of sirtuins and resulting increases in cellular protein deacetylation (ScienceDirect Topics, n.d.). And in the hepatic system, research has demonstrated that the time of day at which NAD+ precursors are administered can influence how effectively they raise NAD+ levels, tied to circadian regulation of NAMPT activity within the liver (Chini et al., 2024).

What the Salvage Pathway Reveals About NAD+ Supplementation

Understanding the full salvage pathway mechanism clarifies why NAD+ supplementation is more nuanced than simply "taking a precursor."

Because NAMPT activity itself declines with age, and because oral NMN and NR appear to undergo partial gut microbiota conversion before absorption, the practical effect of any given precursor depends on multiple downstream factors: transporter availability, tissue-specific NMNAT expression, existing NAMPT activity, and even the composition of an individual's gut microbiota (Mori et al., 2025; Chini et al., 2024). This is precisely why researchers increasingly caution against assuming that all NAD+ precursors behave identically once ingested, even though they ultimately converge on the same biosynthetic pathway.

Supporting Healthy Ageing

Because the salvage pathway's efficiency depends on multiple interacting factors, from NAMPT activity to circadian rhythm to tissue-specific demand, supporting NAD+ metabolism works best as a broad, lifestyle-integrated strategy.

Regular exercise has been directly linked to improved salvage pathway function in skeletal muscle, while consistent sleep patterns may help preserve the circadian regulation that governs NAMPT activity throughout the day (Su et al., 2024; Chini et al., 2024).

Supplements may provide additional support, but they work best as part of a broader, multi-pathway approach addressing NAD+ synthesis, mitochondrial function and inflammation together, an approach explored in more detail on Longevita's science page.

How Longevita™ Supports the NAD+ Salvage Pathway

The research summarised here underscores why understanding the salvage pathway matters beyond theory: because NAMPT activity naturally declines with age and precursor absorption is genuinely more complex than commonly assumed, supporting this system benefits from a considered, multi-ingredient approach rather than a single supplement alone.

This is the scientific rationale behind The Longevita™ Supplement, a doctor-formulated, 12-ingredient longevity formula designed to target the key hallmarks of ageing by promoting cellular energy, helping manage senescent cell burden, and strengthening antioxidant and inflammation defence systems.

At its core, Longevita™ combines Nicotinamide Riboside Chloride, which boosts NAD⁺ levels to activate sirtuins and enhance DNA repair, with Nicotinamide, which sustains NAD⁺ pools for mitochondrial energy and antioxidant defence, offering the formula two distinct entry points into the salvage pathway described above. Alongside these precursors, Coenzyme Q10 preserves mitochondrial ATP production and reduces oxidative stress, while Calcium Alpha Ketoglutarate enhances mitochondrial energy and reduces inflammaging via epigenetic modulation, addressing the inflammatory pressure linked to rising CD38 activity that competes with the salvage pathway for NAD+.

To further support the broader cellular systems that depend on a well-regulated NAD+ supply, Longevita™ includes Trans-Resveratrol, which activates SIRT1 for mitochondrial function while promoting autophagy and DNA repair, and Pterostilbene, which activates SIRT1/AMPK pathways to enhance mitochondrial biogenesis with superior bioavailability. Fisetin supports the clearance of senescent cells, Piperine upregulates antioxidant enzymes and enhances mitochondrial biogenesis via PGC-1α, and Ginseng activates antioxidant pathways and promotes autophagy via SIRT1 and FOXO signalling. L-Theanine, Lutein and Hyaluronic Acid extend the formula's support to cognition, visual health and skin.

Formulated by a doctor and longevity specialist, and manufactured in a GMP-certified, USFDA-registered facility with third-party testing for potency and contaminants, Longevita™ is built on the premise, detailed further on our ingredients page, that supporting NAD+ status means engaging the salvage pathway thoughtfully, not simply assuming any single precursor will work identically across every tissue.

The Bottom Line

The NAD+ salvage pathway is the body's primary system for recycling nicotinamide, a by-product of ordinary NAD+ consumption, back into fresh, usable NAD+, through a defined three-step sequence involving NAMPT and the NMNAT enzyme family. Its efficiency depends on multiple interacting factors, including NAMPT activity, tissue-specific demand, circadian rhythm and even how faithfully oral precursors are absorbed before gut microbiota metabolism intervenes.

Understanding this full pathway, not just the headline molecule, offers a far more accurate picture of how NAD+ metabolism actually works, and reinforces why a comprehensive, multi-pathway approach remains the more scientifically grounded way to support cellular ageing.

Explore The Longevita™ Supplement, a doctor-formulated, 12-ingredient longevity formula designed to support NAD+ status, mitochondrial function and cellular resilience as part of a daily routine.

FAQs

1. What is the NAD+ salvage pathway?

The salvage pathway is the primary system cells use to recycle nicotinamide, a by-product generated when NAD+ is consumed by enzymes like sirtuins and PARPs, back into fresh NAD+, through a defined sequence involving the enzymes NAMPT and NMNAT.

2. What is the rate-limiting step of the salvage pathway?

The conversion of nicotinamide into nicotinamide mononucleotide (NMN), catalysed by NAMPT, is considered the rate-limiting step, meaning NAMPT activity effectively sets the pace for the entire pathway.

3. Do NAD+ precursor supplements enter the salvage pathway directly?

Not entirely. Recent research shows that a substantial portion of orally administered NMN and NR undergoes gut microbiota-mediated conversion into nicotinic acid before absorption, meaning some of their effect may occur via the separate Preiss-Handler pathway.

4. Why does the salvage pathway matter for ageing?

Because NAMPT activity declines with age while NAD+-consuming enzymes like CD38 become more active, the salvage pathway's capacity to keep pace with consumption diminishes over time, a key mechanism behind age-related NAD+ decline.

References

Chini, C.C.S. et al. (2024) 'NAD metabolism: role in senescence regulation and aging', Aging Cell, 23(10), e13920.

Grozio, A., Mills, K.F., Yoshino, J., Bruzzone, S., Sociali, G., Tokizane, K., Lei, H.C., Cunningham, R., Sasaki, Y., Migaud, M.E. & Imai, S. (2019) 'Slc12a8 is a nicotinamide mononucleotide transporter', Nature Metabolism, 1(1), pp. 47–57.

Mori, V. et al. (2025) 'Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation', Science Advances, 11.

nmn.com (2021) 'How do NAD+ precursors get incorporated into cells?', nmn.com News.

PubMed (2021) 'NAD+ metabolism and its roles in cellular processes during ageing', PubMed, 33353981.

ScienceDirect Topics (n.d.) 'Nicotinamide nucleotide adenylyltransferase — an overview', ScienceDirect.

Su, M., Qiu, F., Li, Y., Che, T., Li, N. & Zhang, S. (2024) 'Mechanisms of the NAD+ salvage pathway in enhancing skeletal muscle function', Frontiers in Cell and Developmental Biology, 12, 1464815.

Sun, J.Y., Wang, Z.F., Xu, W.H. & Zhao, J. (2025) 'NAD+ glycohydrolases-CD38 as a therapeutic target in ageing: physiological roles, molecular mechanisms, and future opportunities in anti-ageing research', Biochemical and Biophysical Research Communications, in press.